Skip to content

Reassessment of amphetamine- and phencyclidine-induced locomotor hyperactivity as a model of psychosis-like behavior in rats.

Snezana Kusljic, Maarten Van den Buuse, Andrea Gogos

Journal of Integrative Neuroscience January 28, 2022 DOI: 10.31083/j.jin2101017 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Animal experiment Peer reviewed
Sample size 32
Population Rats
Interventions Haloperidol Prazosin Ritanserin
Dose Haloperidol 0.05 mg/kg, Prazosin 2 mg/kg, Ritanserin 1 mg/kg
Duration 90 minutes after injection
Topics Serotonin
Keywords Amphetamine Dopamine Noradrenaline Phencyclidine Psychosis
Key findings Pre-treatment with haloperidol or prazosin reduced amphetamine-induced hyperactivity, but none of the pre-treatments significantly altered phencyclidine-induced hyperlocomotion.

Abstract

Locomotor hyperactivity induced by psychotomimetic drugs, such as amphetamine and phencyclidine, is widely used as an animal model of psychosis-like behaviour and is commonly attributed to an interaction with dopamine release and N-methyl-D-aspartate (NMDA) receptors, respectively. However, what is often not sufficiently taken into account is that the pharmacological profile of these drugs is complex and may involve other neurotransmitter/receptor systems. Therefore, this study aimed to assess the effect of three antagonists targeting different monoamine pathways on amphetamine- and phencyclidine-induced locomotor hyperactivity. A total of 32 rats were pre-treated with antagonists affecting dopaminergic, noradrenergic and serotonergic transmission: haloperidol (0.05 mg/kg), prazosin (2 mg/kg) and ritanserin (1 mg/kg), respectively. After 30 min of spontaneous activity, rats were injected with amphetamine (0.5 mg/kg) or phencyclidine (2.5 mg/kg) and distance travelled, stereotypy and rearing recorded in photocell cages over 90 min. Pre-treatment with haloperidol or prazosin both reduced amphetamine-induced hyperactivity although pre-treatment with ritanserin had only a partial effect. None of the pre-treatments significantly altered the hyperlocomotion effects of phencyclidine. These findings suggest that noradrenergic as well as dopaminergic neurotransmission is critical for amphetamine-induced locomotor hyperactivity. Hyperlocomotion effects of phencyclidine are dependent on other factors, most likely NMDA receptor antagonism. These results help to interpret psychotomimetic drug-induced locomotor hyperactivity as an experimental model of psychosis.

Comparable studies

Other preclinical and animal studies on serotonin, most cited first.

Citations in the library

Explore topics